tbuckley/cabot-search huggingface dataset:
P85 Virtual lung cancer clinic: early experience and feasibility
Authors: JF Faccenda, LD Calvert, SO Brij
Journal: Thorax (2016)

<h3>Background</h3> With increased public awareness, cough campaigns and incidental nodules on computed tomography (CT), referrals on a Lung Cancer Pathway (LC) have risen significantly. Safe and effective methods to transfer patients to Respiratory Pathways (RP) are essential. <h3>Aims</h3> to evaluate a chose and book, virtual Lung Cancer Clinic (VLCC) to facilitate non-face-to-face “blind” rapid patient assessment, next investigation and appropriate out-patient review. <h3>Methods</h3> A retrospective review of all referrals during the period March–May 2016 was undertaken to assess whether blind clinical decision-making at point of referral was sufficient to plan on-going management. <h3>Results</h3> 60 referrals were reviewed in VLCC by a Lung Cancer Consultant Physician (average time from referral 2 days, range 0–4 days) as their first 2 week wait appointment. 17 (28%) patients had a final diagnosis of Lung Cancer (histological 12, radiological 5). Only 29/60 (48%) were of an acceptable quality for blind decision making. 16 (27%) referrals did not have sufficient information provided to allow any decision to be made and further information from the GP was requested. 26 referrals (43%) were removed from CP onto RP at VLCC review: 14 did not require a CT; 12 scans were undertaken (7 high resolution CT, 1 CT pulmonary angiogram, 4 staging CT), 8 prior to clinic attendance. 34 referrals (57%) remained on CP: 30 (88%) proceeded to staging CT with average wait 12 days (range 3–17 days) from referral, all performed prior to clinic attendance. 1/34 died prior to clinic attendance. 3/34 were scanned before VLCC. A further 8 referrals were removed from CP after imaging. Thus, only 36/60 (60%) referrals were seen in the Lung Cancer Clinic. There was appropriate pathway change in 30% of referrals to General Respiratory (25%) and Pleural Clinic (5%). <h3>Conclusion</h3> The VLCC can effectively assess and plan next investigation with appropriate clinic follow-up for suspected Lung Cancer patients. However, blind decision-making relies upon good clinical information from the referrer and administrative time can be wasted chasing this. Our data confirms that the VLCC facilitates efficient use of Out-patient and Radiology Services.
Letter in response to glucagon-like peptide-1 mediates cardioprotection by remote ischaemic conditioning
Authors: Joel P. Giblett, Stephen P. Hoole
Journal: Cardiovascular Research (2016)

We read with interest the study by Basalay et al 1 recently published in Cardiovascular Research investigating the mechanism of remote ischaemic conditioning (RIc) signalling. Whilst the results are intriguing, a number of unresolved issues remain when considering RIc in humans.

First, the authors state that Glucagon-like Peptide 1 (GLP-1) had a protective effect against ischaemia-reperfusion injury in humans. It is noteworthy that the cardioprotective effect of GLP-1 in humans is …
Maintenance Therapy with Nilotinib (Tasigna) Post Allogeneic Stem Cell Transplantation (AlloSCT) for Advanced (&gt;CP1) Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Authors: Arnon Nagler, Yulia Volchek, Nira Bloom, Raz Somech, Ronit Yerushalmi, Avichai Shimoni
Journal: Blood (2011)
P90 The north-south divide: regional inequalities in demographic characteristics and clinical outcomes in patients with cystic fibrosis in england–a population based cross-sectional study using uk CF registry data
Authors: S Nyangoma, V Rajabzadeh-Heshejin, P Cullinan, J Samption
Journal: Thorax (2016)

<h3>Background</h3> For many diseases including cancer, the inequalities in key clinical outcomes are known to be wider in the economically disadvantaged Northern England (NE) compared to the more affluent South England (SE) (Shack, <i>et al</i>, 2008). This study aimed to investigate the North-South divide in demographic characteristics and clinical outcomes in cystic fibrosis (CF) patients in England. <h3>Methods</h3> This was a cross-sectional study of patients with CF living in the SE and NE and registered on the UK CF Registry in 2010. Clinical data from Annual Review Encounter (ARE) of that year included demographics, prescription records and clinical outcomes: FEV1%predicted and chronic infections. Descriptive statistics were adopted to summarise categorical and continuous outcomes. Wilcoxon test and t-test was used to compare continuous outcomes, while two-sample test for equality of proportions was used to compare prevalence of infections and drug use. <h3>Results</h3> The study cohort included 1265 children and 1752 adults from SE and 1483 children and 1917 adults from NE. For children: lung function (FEV1%), adjusted for age and sex was significantly higher in SE (84.51% vs 81.57%, p &lt; 0.01). However, rates of <i>Pseudomonas aeuginosa</i>, Burkholderia cepacia and MRSA were similar. Significantly higher proportions of patients were diagnosed before turning 3 months in the NE compared to SE (46.76% vs 42.43%). In adults: in the NE the BMI was higher 22.35 vs 21.99 (p &lt; 0.01) as was the FEV1%p, adjusted for age and sex (66.73% vs 64.69%, p = 0.04). Patients in SE were more frequently prescribed mucolytics (Dornase Alfa and Hypertonic Saline). In NE they more frequently used chronic macrolides. There were higher rates of PA, Bcc and MRSA in NE. The rates of MSSA and NTM were higher in the SE. <h3>Conclusions</h3> There is a north-south divide in demographic characteristics and clinical outcomes in cystic fibrosis (CF) patients in England. In SE children have higher lung function. However, adults in the NE seem to have higher lung function compared to adults in SE. A single year cohort is not sufficient to deduce if these differences affect longer-term outcomes, like survival and requires further investigation.
P3.01-018 Reproducibility in Classification of Small Lung Adenocarcinomas: An International Interobserver Study
Authors: Angela Shih, Alona Muzikansky, Emine Bozkurtlar, Jin-Haeng Chung, Yuko Minami, Lida Hariri, Andre Moreira, Hironori Uruga, He Wang, Akihiko Yoshizawa, Mari Mino-Kenudson
Journal: Journal of Thoracic Oncology (2017)
P2.04-006 Updated Incidence of Thymic Epithelial Tumors (TET) in France and Clinical Presentation at Diagnosis
Authors: Maria Bluthgen, Eric Dansin, Mallorie Kerjouan, Julien Mazieres, Eric Pichon, François Thillays, Gilbert Massard, Xavier Quantin, Youssef Oulkhouir, Virginie Westeel, Luc Thiberville, Christelle Clément-Duchêne, Pascal Alexandre Thomas, Nicolas Girard, Benjamin Besse
Journal: Journal of Thoracic Oncology (2017)
Dental problems account for one in 140 emergency department visits
Authors: Susan Mayor
Journal: BMJ (2017)

One in every 140 visits to a large UK hospital emergency department is for dental problems, a large cross sectional study has shown.1

Almost a third of the adult UK population seek dental care only when they have acute problems and frequently consult healthcare professionals other than dentists.

Researchers carried out a cross sectional study to collect anonymised data from records of all patient visits to the medical emergency department at the Royal Victoria Hospital in Newcastle upon Tyne, as part of a service evaluation. They analysed …
Genome-Wide Profiling of Endothelial Progenitor Cells in Multiple Myeloma: Overlaps with Myeloma Tumor Cells and Common Cancer Gene-Pathways.
Authors: Marc J. Braunstein, Daniel R. Carrasco, Fabien Campagne, Piali Mukherjee, Kumar Sukhdeo, Alexei Protopopov, Kenneth C. Anderson, Olcay A. Batuman
Journal: Blood (2007)
Novel Synthetic Histone Deacetylase Inhibitor, SK-7041, Has Potent Anti-Proliferative Activity in Acute Myeloid Leukemia Cell Lines.
Authors: Sung-Soo Yoon, Eunkyung Bae, Juwon Park, Yongjun Cha, Young Y. Lee, Byoung K. Kim
Journal: Blood (2007)
Murine Spherocytosis: Evidence for a Functional Interaction between Protein 4.1 and Na/H Exchange and for a “Protective” Role of the Gardos Channel Against Hemolysis.
Authors: Lucia De Franceschi, Alicia Rivera, Isabel Bize, Mark Fleming, Luanne L. Peters, Philippe Gascard, Narla Mohandas, Carlo Brugnara
Journal: Blood (2004)
P2.03a-026 Pemetrexed (Alimta) in Maintenance Therapy of 194 Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Authors: Jana Skrickova, Zbynek Bortlicek, Karel Hejduk, Milos Pesek, Vitezslav Kolek, Leona Koubkova, Marketa Cernovska, Jaromir Roubec, Libor Havel, Frantisek Salajka, Milada Zemanová, Dimka Sixtova, Helena Coupkova, Marcela Tomiskova, Monika Satankova, Andrea Benejova, Michal Hrnčiarik, Ivona Gragarkova, Miloslav Marel
Journal: Journal of Thoracic Oncology (2017)
P3.02a-016 Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC)
Authors: James Chih-Hsin Yang, Sai-Hong Ou, Luigi De Petris, Shirish Gadgeel, Leena Gandhi, Dong-Wan Kim, Fabrice Barlesi, Ramaswamy Govindan, Anne-Marie Dingemans, Lucio Crinò, Hervé Léna, Sanjay Popat, Jin Seok Ahn, Eric Dansin, Sophie Golding, Walter Bordogna, Bogdana Balas, Peter N. Morcos, Ali Zeaiter, Alice Shaw
Journal: Journal of Thoracic Oncology (2017)
S105 Pneumococcal serotypes implicated in adult pneumococcal pneumonia, 9 years following the introduction of the infant vaccine programme in the uk
Authors: P Daniel, D Ashton, C Sheppard, S Eletu, P Sandu, D Litt, N Fry, WS Lim
Journal: Thorax (2016)

<h3>Background</h3> The introduction of the pneumococcal conjugate vaccines into infant vaccination schedules, has led to a change in the serotype prevalence causing adult pneumococcal disease, through the process of herd immunity. Whilst there are national surveillance programmes informing the changes in serotype in invasive pneumococcal disease, there are no comparable data to demonstrate the ongoing vaccine effect on non-invasive pneumococcal community acquired pneumonia (CAP), the most common clinical manifestation of pneumococcal disease in adults. <h3>Methods</h3> Consecutive adult patients admitted to 2 hospitals, covering the catchment area of a large UK city, with a diagnosis of CAP were studied prospectively, over a 1 year period between September 2014 and 2015. A novel multiplex assay capable of detecting 24 serotypes/serogroups of <i>Streptococcus pneumoniae</i> was performed on patient urine. Pneumococcal infection was determined by identification of the organism from either sterile sites and/or detection of pneumococcal antigen or serotype in urine samples. <h3>Results</h3> Of 478 individuals admitted with CAP, pneumococcal disease was diagnosed in 166 (34.7%) cases. Pneumococcal CAP diagnosis was made by blood culture, pneumococcal urinary antigen detection and urinary serotype detection in 23 (13.9%), 61 (36.8%) and 149 (89.8%) cases respectively. A definitive single serotype was identified in 116 individuals; the most commonly observed were serotypes 3 and 8 (31 cases each, 26.7%), followed by serogroup 15 (14 cases, 12.1%), 17F (10 cases, 8.6%) and 33A/B/D/E (9 cases, 7.8%). <h3>Conclusion</h3> This is the first report on extended serotype distribution implicated in adult pneumococcal CAP, 9 years after the introduction of the UK infant vaccination programme. In this era of high infant vaccine coverage, whilst the majority of isolates are non-vaccine types due to the effects of serotype replacement, serotype 3 remains a common cause of adult pneumococcal CAP and may reflect inadequate serotype specific vaccine effectiveness.
P2.04-017 Prognostic Relevance of PD-1/PD-L1 Pathway in Thymic Malignancies with Combined Immunohystochemical and Biomolecular Approach
Authors: Rossana Berardi, Gaia Goteri, Alessandro Brunelli, Silvia Pagliaretta, Vittorio Paolucci, Miriam Caramanti, Silvia Rinaldi, Majed Refai, Cecilia Pompili, Francesca Morgese, Mariangela Torniai, Sonia Pasquini, Paola Mazzanti, Azzurra Onofri, Francesca Bianchi, Armando Sabbatini, Stefano Cascinu
Journal: Journal of Thoracic Oncology (2017)
Balloon Angioplasty versus Implantation of Nitinol Stents in the Superficial Femoral Artery
Authors: Martin Schillinger, Schila Sabeti, Christian Loewe, Petra Dick, Jasmin Amighi, Wolfgang Mlekusch, Oliver Schlager, Manfred Cejna, Johannes Lammer, Erich Minar
Journal: New England Journal of Medicine (2006)

Because stent implantation for disease of the superficial femoral artery has been associated with high rates of late clinical failure, percutaneous transluminal angioplasty is preferred for endovascular treatment, and stenting is recommended only in the event of suboptimal technical results. We evaluated whether primary implantation of a self-expanding nitinol (nickel-titanium) stent yielded anatomical and clinical benefits superior to those afforded by percutaneous transluminal angioplasty with optional secondary stenting.We randomly assigned 104 patients who had severe claudication or chronic limb ischemia due to stenosis or occlusion of the superficial femoral artery to undergo primary stent implantation (51 patients) or angioplasty (53 patients). Restenosis and clinical outcomes were assessed at 6 and 12 months.The mean (+/-SD) length of the treated segment was 132+/-71 mm in the stent group and 127+/-55 mm in the angioplasty group. Secondary stenting was performed in 17 of 53 patients (32 percent) in the angioplasty group, in most cases because of a suboptimal result after angioplasty. At 6 months, the rate of restenosis on angiography was 24 percent in the stent group and 43 percent in the angioplasty group (P=0.05); at 12 months the rates on duplex ultrasonography were 37 percent and 63 percent, respectively (P=0.01). Patients in the stent group were able to walk significantly farther on a treadmill at 6 and 12 months than those in the angioplasty group.In the intermediate term, treatment of superficial-femoral-artery disease by primary implantation of a self-expanding nitinol stent yielded results that were superior to those with the currently recommended approach of balloon angioplasty with optional secondary stenting. (ClinicalTrials.gov number, NCT00281060.).
P2.01-079 The Serum Levels of Alpha-1 Antitrypsin Are Strongly Associated with Its Local Production by Tumor Cells in NSCLC Patients
Authors: Adam Szpechcinski, Renata Langfort, Emilia Debek, Dorota Giedronowicz, Mateusz Florczuk, Michal Komorowski, Wlodzimierz Kupis, Piotr Rudzinski, Jolanta Zaleska, Tadeusz Orlowski, Kazimierz Roszkowski-Sliz, Joanna Chorostowska-Wynimko
Journal: Journal of Thoracic Oncology (2017)
High Doses of CD34+ Cells Chemomobilized with G-CSF PBPC Collection Had Greater CD34(+) Cells Collected Than G-CSF Alone and Trended toward Reduced Progression Rate after Autologous PBPC Transplantation for Breast Cancer in a Phase III Trial.
Authors: James L. Gajewski, Rima Saliba, Gabriela Rondon, Naoto T. Ueno, Michele L. Donato, Paolo Anderlini, Martin Korbling, John D. McMannis, Sergio A. Giralt, Issa F. Khouri, Rakesh Mehra, Richard E. Champlin
Journal: Blood (2004)
P3.02a-020 Clinical Failure to Crizotinib in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancers
Authors: Jin Kang, Huajun Chen, Jin -Ji Yang, Qing Zhou, Hai-Yan Tu, Zhen Wang, Jia-Xin Lin, Yi Long Wu
Journal: Journal of Thoracic Oncology (2017)
Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer
Authors: Carl Koschmann, Felipe J. Nunez, Flor Mendez, Jacqueline A. Brosnan-Cashman, Alan K. Meeker, Pedro R. Lowenstein, Maria G. Castro
Journal: Cancer Research (2017)

Abstract Genes encoding proteins that regulate chromatin structure and DNA modifications [i.e., chromatin regulatory factors (CRF)] and genes encoding histone proteins harbor recurrent mutations in most human cancers. These mutations lead to modifications in tumor chromatin and DNA structure and an altered epigenetic state that contribute to tumorigenesis. Mutated CRFs have now been identified in most types of cancer and are increasingly regarded as novel therapeutic targets. In this review, we discuss DNA alterations in CRFs and how these influence tumor chromatin structure and function, which in turn leads to tumorigenesis. We also discuss the clinical implications and review concepts of targeted treatments for these mutations. Continued research on CRF mutations will be critical for our future understanding of cancer biology and the development and implementation of novel cancer therapies. Cancer Res; 77(2); 227–33. ©2017 AACR.
Platelet-Lysate for In Vitro Expansion of Human Multipotent Mesenchymal Stromal Cells in Approaches of Cell-Therapy.
Authors: Maria Ester Bernardo, Maria Antonietta Avanzini, Cesare Perotti, Angela M. Cometa, Antonia Moretta, Elisa Lenta, Claudia Del Fante, Francesca Novara, Orsetta Zuffardi, Rita Maccario, Franco Locatelli
Journal: Blood (2006)
P1.02-047 Effect of Dasatinib on EMT-Mediated-Mechanism of Resistance against EGFR Inhibitors in Lung Cancer Cells
Authors: Yuichi Sesumi, Kenichi Suda, Hiroshi Mizuuchi, Yoshihisa Kobayashi, Masaya Nishino, Masato Chiba, Masaki Shimoji, Katsuaki Sato, Kenji Tomizawa, Toshiki Takemoto, Tetsuya Mitsudomi
Journal: Journal of Thoracic Oncology (2017)
Abstract A06: Combination of TRAIL and Chal-24 synergistically induces autophagy-mediated apoptosis in lung cancer cells
Authors: Xiuling Xu, Jennings Xu, Shaoqing Shi, Qiong Wang, Bryanna Saxton, Chengguo Xing, Yong Lin
Journal: Clinical Cancer Research (2017)

Abstract Combination chemotherapy is an effective strategy for increasing anticancer efficacy, reducing side effects and alleviating drug resistance. Here we report that combination of the recently identified novel chalcone derivative, chalcone-24 (Chal-24), and TNF-related apoptosis-inducing ligand (TRAIL) significantly increases cytotoxicity in lung cancer cells. Chal-24 treatment significantly enhanced TRAIL-induced activation of caspase-8 and caspase-3, and the cytotoxicity induced by combination of these agents was effectively suppressed by the pan-caspase inhibitor z-VAD-fmk. Chal-24 and TRAIL combination suppressed expression of cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein large (c-FLIPL) and cellular inhibitor of apoptosis proteins (c-IAPs), and ectopic expression of c-FLIPL and c-IAPs inhibited the potentiated cytotoxicity. In addition, TRAIL and Chal-24 cooperatively activated autophagy. Suppression of autophagy effectively attenuated cytotoxicity induced by the combination of Chal-24 and TRAIL, which was associated with attenuation of c-FLIPL and c-IAPs degradation. Altogether, these results suggest that Chal-24 potentiates the anticancer activity of TRAIL through autophagy-mediated degradation of c-FLIPL and c-IAPs, and that combination of Chal-24 and TRAIL could be an effective approach in improving chemotherapy efficacy. Citation Format: Xiuling Xu, Jennings Xu, Shaoqing Shi, Qiong Wang, Bryanna Saxton, Chengguo Xing, Yong Lin. Combination of TRAIL and Chal-24 synergistically induces autophagy-mediated apoptosis in lung cancer cells. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr A06.
OA15.03 Comparison of Prognosis between Lobectomy and Sublobar Resection for Clinical Stage I Non-Small Cell Lung Cancer with Interstitial Lung Disease
Authors: Yasuhiro Tsutani, Takeshi Mimura, Yuichiro Kai, Masaoki Ito, Yoshinori Handa, Norifumi Tsubokawa, Keizo Misumi, Hideaki Hanaki, Yoshihiro Miyata, Morihito Okada
Journal: Journal of Thoracic Oncology (2017)
Abstract A32: Upregulation of the Notch signaling pathway is associated with mortality and in vitro cell invasion in squamous cell carcinoma of the oral cavity
Authors: Alice N. Weaver, Tiffiny S. Cooper, Deborah Della Manna, Shi Wei, Eben L. Rosenthal, Eddy S. Yang
Journal: Clinical Cancer Research (2017)

Abstract Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease with low survival rates, which have not significantly improved despite advances in surgery and radiotherapy. Although human papillomavirus is a strong predictor of outcomes in oropharyngeal tumors, other HNSCC subtypes lack reliable prognostic and therapeutic biomarkers. The purpose of this study was to identify molecular targets to improve the management of oral cavity SCC (OSCC). We isolated RNA from 19 OSCCs treated surgically at UAB and evaluated gene expression using the NanoString nCounter system and PanCancer Pathways analysis module. Results were confirmed using data from the oral cavity anatomic subdivision of the Head and Neck Squamous Cell Carcinoma cancer study generated by the TCGA Research Network. Associated in vitro phenotype was assessed in HNSCC cell lines UM-SCC1, UM-SCC6 and FaDu treated with the activating Notch ligand DLL4 and included evaluation of gene expression, proliferation, cell cycle, migration, invasion, and radiosensitivity. We identified a significant association between upregulation of the Notch pathway and mortality in both the UAB and TCGA OSCC sample sets. In vitro activation of Notch signaling altered transcription in a pattern similar to that found in patient samples from the mortality cohorts. HNSCC cells with Notch activation had increased expression of pro-invasive genes FGF1, IL1B, SIX1, and CCNA1. In addition, Notch activated cells displayed increased cell migration and invasion. Proliferation, cell cycle distribution, and radiosensitivity were unchanged in ligand-treated cells. Our results identify a subset of OSCC patients who have increased Notch pathway activity and worsened outcomes. These clinical findings may reflect a more invasive cell phenotype driven by Notch-mediated changes in transcription. Additional studies are needed to fully elucidate the mechanism underlying this association and to investigate the efficacy of therapies targeting Notch signaling in OSCC. Citation Format: Alice N. Weaver, Tiffiny S. Cooper, Deborah Della Manna, Shi Wei, Eben L. Rosenthal, Eddy S. Yang. Upregulation of the Notch signaling pathway is associated with mortality and in vitro cell invasion in squamous cell carcinoma of the oral cavity. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr A32.
Graft Source and HLA-Matching Degree-Based Analyses of Long-Term Outcomes of Unrelated Donor Transplants in Adult High-Risk Acute Lymphoblastic Leukemia: Similar Outcomes Between Bone Marrow and Peripheral Blood Progenitor Cells Transplants,
Authors: Seok Lee, Seung-Ah Yahng, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Nak-Gyun Chung, Hee-Je Kim, Chang-Ki Min, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park
Journal: Blood (2011)
Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLD-1 Trial
Authors: Ralf Trappe, Stephan H.K. Oertel, Veronique Leblond, Peter Mollee, Monica Sender, Petra Reinke, Ruth Neuhaus, Hans Lehmkuhl, Heinz A. Horst, Gilles Andre Salles, Franck Morschhauser, Arnaud Jaccard, Thierry Lamy, Malte Leithäuser, Ioannis Anagnostopoulos, Martine Raphael, Hanno Riess, Sylvain Choquet
Journal: Blood (2011)
P3.01-003 Thyroid Transcription Factor-1 (TTF-1) Expression for Intraoperative Diagnosis Using the Rapid-Immunohistochemistry (IHC) in Lung Tumors
Authors: Hayato Konno, Hajime Saito, Nobuyasu Kurihara, Satoshi Fujishima, Maiko Atari, Yuko Hiroshima, Hiroshi Nanjo, Yoshihiro Minamiya
Journal: Journal of Thoracic Oncology (2017)
Usefulness of Recombinant Human Erythropoietin during Induction-Consolidation Chemotherapy for Chronic Hematological Lymphoid Malignancies: Improving Stem Cell Harvest and Reducing Blood-Product Support for Patients Receiving Autologous Stem-Cell Transplantation.
Authors: Fontanet D. Bijou, Reza Tabrizi, Thibaut Legay, Cyril Melot, Krimo Bouabdallah, Arnaud Pigneux, Jean-Michel Boiron, Gerald Marit
Journal: Blood (2005)